EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats

Britta Lipinski, Paul Arras, Lukas Pekar, Daniel Klewinghaus, Ammelie Svea Boje, Simon Krah, Jasmin Zimmermann, Katja Klausz, Matthias Peipp, Vanessa Siegmund, Andreas Evers, Stefan Zielonka iD

Protein Science · 2023

DOI: 10.1002/pro.4593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Science, 2023. Verfasst von Britta Lipinski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein, we describe the generation of potent NK cell engagers (NKCEs) based on single domain antibodies (sdAbs) specific for NKp46 harboring the humanized Fab version of Cetuximab for tumor targeting. After immunization of camelids, a plethora of different VHH domains were retrieved by yeast surface display. Upon reformatting into Fc effector‐silenced NKCEs targeting NKp46 and EGFR in a strictly monovalent fashion, the resulting bispecific antibodies elicited potent NK cell‐mediated killing of EGFR‐overexpressing tumor cells with potencies (EC 50 killing) in the picomolar range. This was further augmented via co‐engagement of Fcγ receptor IIIa (FcγRIIIa). Importantly, NKp46‐specific sdAbs enabled the construction of various NKCE formats with different geometries and valencies which displayed favorable biophysical and biochemical properties without further optimization. By this means, killing capacities were further improved significantly. Hence, NKp46‐specific sdAbs are versatile building blocks for the construction of different NKCE formats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesAntibodies, BispecificNeoplasmsHumansKiller Cells, NaturalErbB ReceptorsCell Line, Tumor

Stichwörter der Autor:innen

ADCCNK cell engagerNK cell redirectionNKp46VHHantibody engineeringbispecific antibodymultifunctional antibodysingle domain antibodyvalencies

Substanzen

Single-Domain AntibodiesAntibodies, BispecificErbB Receptors

Autor:innen und Institutionen

  • Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
  • Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
  • Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.
  • Protein and Cell Sciences, Merck Healthcare KGaA, Darmstadt, Germany.
  • Computational Chemistry and Biology, Merck Healthcare KGaA, Darmstadt, Germany.

ORCID-Profile: Stefan Zielonka

Zitieren

APA

Lipinski, B., Arras, P., Pekar, L., Klewinghaus, D., Boje, A. S., Krah, S., Zimmermann, J., Klausz, K., Peipp, M., Siegmund, V., Evers, A., & Zielonka, S. (2023). NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science. https://doi.org/10.1002/pro.4593

Vancouver

Lipinski B, Arras P, Pekar L, Klewinghaus D, Boje AS, Krah S, et al. NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science. 2023. doi:10.1002/pro.4593

BibTeX
@article{Lipinski2023,
  author = {Lipinski, Britta and Arras, Paul and Pekar, Lukas and Klewinghaus, Daniel and Boje, Ammelie Svea and Krah, Simon and Zimmermann, Jasmin and Klausz, Katja and Peipp, Matthias and Siegmund, Vanessa and Evers, Andreas and Zielonka, Stefan},
  title = {NKp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats},
  journal = {Protein Science},
  year = {2023},
  doi = {10.1002/pro.4593}
}
Kostenlos starten →